{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:24:20Z","timestamp":1792041860400,"version":"4.4.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Cannabichromene (CBC) is a phytocannabinoid commonly found in cannabis, yet its acute post-dose pharmacokinetics (PK) have not been examined in humans. This is a secondary data analysis from a trial investigating Spectrum Yellow oil, an oral cannabis product used for medical purposes that contained 20\u00a0mg cannabidiol (CBD), 0.9\u00a0mg \u0394<jats:sup>9<\/jats:sup>-tetrahydrocannabinol (THC), and 1.1\u00a0mg CBC, per 1\u00a0mL of oil.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Participants (<jats:italic>N<\/jats:italic>\u2009=\u200943) were randomized to one of 5 groups: 120\u00a0mg CBD, 5.4\u00a0mg THC, and 6.6\u00a0mg CBC daily; 240\u00a0mg CBD, 10.8\u00a0mg THC, and 13.2\u00a0mg CBC daily; 360\u00a0mg CBD, 16.2\u00a0mg THC, and 19.8\u00a0mg CBC daily; 480\u00a0mg CBD, 21.6\u00a0mg THC, and 26.4\u00a0mg CBC daily; or placebo. Study medication was administered every 12\u00a0h for 7\u00a0days. Plasma CBC concentrations were analyzed by a validated two-dimensional high-performance liquid chromatography\u2013tandem mass spectrometry assay.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After a single dose and after the final dose, the <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> of CBC increased by 1.3\u20131.8-fold for each twofold increase in dose; the <jats:italic>t<\/jats:italic><jats:sub>max<\/jats:sub> range was 1.6\u20134.3\u00a0h. Based on the ratio of administered CBD, THC, and CBC to the plasma concentration, the dose of CBD was 18 times higher than the dose of CBC, yet the AUC<jats:sub>0\u2013<jats:italic>t<\/jats:italic><\/jats:sub> of CBD was only 6.6\u20139.8-fold higher than the AUC<jats:sub>0\u2013<jats:italic>t<\/jats:italic><\/jats:sub> of CBC; the dose of THC was similar to the dose of CBC, yet THC was quantifiable in fewer plasma samples than was CBC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>CBC may have preferential absorption over CBD and THC when administered together.<\/jats:p>\n                <jats:p><jats:italic>Trial Registration<\/jats:italic>: Australian New Zealand Clinical Trials Registry #ACTRN12619001450101, registered 18 October 2019.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-021-03232-8","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T03:11:37Z","timestamp":1634613097000},"page":"259-265","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and \u03949-tetrahydrocannabinol: a pilot study"],"prefix":"10.1007","volume":"78","author":[{"given":"Erica N.","family":"Peters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"MacNair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Mosesova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Christians","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sempio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jost","family":"Klawitter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Hunter","family":"Land","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Ware","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Turcotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel O.","family":"Bonn-Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"key":"3232_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.11868","author":"KP Hill","year":"2019","unstructured":"Hill KP (2019) Medical use of cannabis in 2019. JAMA. https:\/\/doi.org\/10.1001\/jama.2019.11868","journal-title":"JAMA"},{"key":"3232_CR2","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.tips.2009.07.006","volume":"30","author":"AA Izzo","year":"2009","unstructured":"Izzo AA, Borrelli F, Capasso R et al (2009) Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30:515\u2013527. https:\/\/doi.org\/10.1016\/j.tips.2009.07.006","journal-title":"Trends Pharmacol Sci"},{"key":"3232_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1021\/np50008a001","volume":"43","author":"CE Turner","year":"1980","unstructured":"Turner CE, Elsohly MA, Boeren EG (1980) Constituents of Cannabis sativa L. XVII. A review of the natural constituents. J Nat Prod 43:169\u2013234. https:\/\/doi.org\/10.1021\/np50008a001","journal-title":"J Nat Prod"},{"key":"3232_CR4","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/j.1556-4029.2010.01441.x","volume":"55","author":"Z Mehmedic","year":"2010","unstructured":"Mehmedic Z, Chandra S, Slade D et al (2010) Potency trends of Delta9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 55:1209\u20131217. https:\/\/doi.org\/10.1111\/j.1556-4029.2010.01441.x","journal-title":"J Forensic Sci"},{"key":"3232_CR5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1556-4029.2007.00603.x","volume":"53","author":"DJ Potter","year":"2008","unstructured":"Potter DJ, Clark P, Brown MB (2008) Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci 53:90\u201394. https:\/\/doi.org\/10.1111\/j.1556-4029.2007.00603.x","journal-title":"J Forensic Sci"},{"issue":"7","key":"3232_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070052","volume":"8","author":"W Swift","year":"2013","unstructured":"Swift W, Wong A, Li KM et al (2013) Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PLoS One 8(7):e70052. https:\/\/doi.org\/10.1371\/journal.pone.0070052","journal-title":"PLoS ONE"},{"key":"3232_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ntt.2014.09.003","volume":"46","author":"S Rosenthaler","year":"2014","unstructured":"Rosenthaler S, Pohn B, Kolmanz C et al (2014) Differences in receptor binding affinity of several phytocannabinoids do not explain their effects on neural cell cultures. Neurotoxicol Teratol 46:49\u201356. https:\/\/doi.org\/10.1016\/j.ntt.2014.09.003","journal-title":"Neurotoxicol Teratol"},{"key":"3232_CR8","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.1111\/bph.14815","volume":"176","author":"M Udoh","year":"2019","unstructured":"Udoh M, Santiago M, Devenish S et al (2019) Cannabichromene is a cannabinoid CB2 receptor agonist. Br J Pharmacol 176:4537\u20134547. https:\/\/doi.org\/10.1111\/bph.14815","journal-title":"Br J Pharmacol"},{"key":"3232_CR9","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1124\/jpet.106.105247","volume":"318","author":"A Ligresti","year":"2006","unstructured":"Ligresti A, Moriello AS, Starowicz K et al (2006) Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 318:1375\u20131387. https:\/\/doi.org\/10.1124\/jpet.106.105247","journal-title":"J Pharmacol Exp Ther"},{"key":"3232_CR10","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.001166.x","volume":"163","author":"L De Petrocellis","year":"2011","unstructured":"De Petrocellis L, Ligresti A, Moriello AS et al (2011) Effects of cannabinoids and cannabinoid-enriched cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. British J Pharmacol 163:1479\u20131494. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.001166.x","journal-title":"British J Pharmacol"},{"key":"3232_CR11","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1124\/jpet.107.134809","volume":"325","author":"L De Petrocellis","year":"2008","unstructured":"De Petrocellis L, Vellani V, Schiano-Moriello A et al (2008) Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J Pharmacol Exp Ther 325:1007\u20131015. https:\/\/doi.org\/10.1124\/jpet.107.134809","journal-title":"J Pharmacol Exp Ther"},{"key":"3232_CR12","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.neuint.2013.08.002","volume":"63","author":"N Shinjyo","year":"2013","unstructured":"Shinjyo N, Di Marzo V (2013) The effect of cannabichromene on adult neural stem\/progenitor cells. Neurochem Int 63:432\u2013437. https:\/\/doi.org\/10.1016\/j.neuint.2013.08.002","journal-title":"Neurochem Int"},{"key":"3232_CR13","doi-asserted-by":"publisher","first-page":"283S","DOI":"10.1002\/j.1552-4604.1981.tb02606.x","volume":"21","author":"CE Turner","year":"1981","unstructured":"Turner CE, Elsohly MA (1981) Biological activity of cannabichromene, its homologs and isomers. J Clin Pharmacol 21:283S-S291. https:\/\/doi.org\/10.1002\/j.1552-4604.1981.tb02606.x","journal-title":"J Clin Pharmacol"},{"key":"3232_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0306-3623(83)90004-6","volume":"14","author":"WM Davis","year":"1983","unstructured":"Davis WM, Hatoum NS (1983) Neurobehavioral actions of cannabichromene and interactions with \u03949-tetrahydrocannabinol. Gen Pharmacol 14:247\u2013252. https:\/\/doi.org\/10.1016\/0306-3623(83)90004-6","journal-title":"Gen Pharmacol"},{"key":"3232_CR15","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1021\/np8002673","volume":"71","author":"G Appendino","year":"2008","unstructured":"Appendino G, Gibbons S, Giana A et al (2008) Antibacterial cannabinoids from Cannabis sativa: a structure-activity study. J Nat Prod 71:1427\u20131430. https:\/\/doi.org\/10.1021\/np8002673","journal-title":"J Nat Prod"},{"key":"3232_CR16","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.drugalcdep.2010.05.019","volume":"112","author":"GT DeLong","year":"2010","unstructured":"DeLong GT, Wolf CE, Poklis A et al (2010) Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by delta(9)-tetrahydrocannabinol. Drug Alcohol Depend 112:126\u2013133. https:\/\/doi.org\/10.1016\/j.drugalcdep.2010.05.019","journal-title":"Drug Alcohol Depend"},{"key":"3232_CR17","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.pbb.2010.03.004","volume":"95","author":"AT El-Alfy","year":"2010","unstructured":"El-Alfy AT, Ivey K, Robinson K et al (2010) Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol Biochem Behav 95:434\u2013442. https:\/\/doi.org\/10.1016\/j.pbb.2010.03.004","journal-title":"Pharmacol Biochem Behav"},{"key":"3232_CR18","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.fitote.2010.04.009","volume":"81","author":"A Tubaro","year":"2010","unstructured":"Tubaro A, Giangaspero A, Sosa S et al (2010) Comparative topical anti-inflammatory activity of cannabinoids and cannabivarins. Fitoterapia 81:816\u2013819. https:\/\/doi.org\/10.1016\/j.fitote.2010.04.009","journal-title":"Fitoterapia"},{"key":"3232_CR19","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/j.1476-5381.2010.01063.x","volume":"162","author":"S Maione","year":"2011","unstructured":"Maione S, Piscitelli F, Gatta L et al (2011) Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. British J Pharmacol 162:584\u2013596. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.01063.x","journal-title":"British J Pharmacol"},{"key":"3232_CR20","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1111\/j.1476-5381.2012.01879.x","volume":"166","author":"AA Izzo","year":"2012","unstructured":"Izzo AA, Capasso R, Aviello G et al (2012) Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. Br J Pharmacol 166:1444\u20131460. https:\/\/doi.org\/10.1111\/j.1476-5381.2012.01879.x","journal-title":"Br J Pharmacol"},{"key":"3232_CR21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/bph.12120","volume":"169","author":"B Romano","year":"2013","unstructured":"Romano B, Borrelli F, Fasolino I et al (2013) The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis. Br J Pharmacol 169:213\u2013229. https:\/\/doi.org\/10.1111\/bph.12120","journal-title":"Br J Pharmacol"},{"key":"3232_CR22","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/FTD.0000000000000427","volume":"39","author":"J Klawitter","year":"2017","unstructured":"Klawitter J, Sempio C, Morlein S et al (2017) An atmospheric pressure chemical ionization MS\/MS assay using online extraction for the analysis of 11 cannabinoids and metabolites in human plasma and urine. Ther Drug Monit 39:556\u2013564. https:\/\/doi.org\/10.1097\/FTD.0000000000000427","journal-title":"Ther Drug Monit"},{"key":"3232_CR23","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3389\/fneur.2019.00716","volume":"10","author":"RJ Huntsman","year":"2019","unstructured":"Huntsman RJ, Tang-Wai R, Alcorn J et al (2019) Dosage related efficacy and tolerability of cannabidiol in children with treatment-resistant epileptic encephalopathy: preliminary results of the CARE-E study. Front Neurol 10:716. https:\/\/doi.org\/10.3389\/fneur.2019.00716","journal-title":"Front Neurol"},{"key":"3232_CR24","doi-asserted-by":"publisher","unstructured":"Peters EN, Mosesova I, MacNair L et al (2021) Safety, pharmacokinetics, and pharmacodynamics of Spectrum Yellow oil in healthy participants. J Anal Toxicol bkab026.\u00a0https:\/\/doi.org\/10.1093\/jat\/bkab026. Online ahead of print","DOI":"10.1093\/jat\/bkab026"},{"key":"3232_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1300\/J175v03n04_02","volume":"3","author":"GW Guy","year":"2004","unstructured":"Guy GW, Robson PJ (2004) A phase I, double blind, three-way crossover study to assess the pharmacokinetic profile of cannabis based medicine extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers (GWPK0215). Journal of Cannabis Therapeutics 3:121\u2013152. https:\/\/doi.org\/10.1300\/J175v03n04_02","journal-title":"Journal of Cannabis Therapeutics"},{"key":"3232_CR26","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1007\/s00213-019-05246-8","volume":"236","author":"TR Arkell","year":"2019","unstructured":"Arkell TR, Lintzeris N, Kevin RC et al (2019) Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Psychopharmacology 236:2713\u20132724. https:\/\/doi.org\/10.1007\/s00213-019-05246-8","journal-title":"Psychopharmacology"},{"key":"3232_CR27","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/01.ftd.0000177223.19294.5c","volume":"27","author":"T Nadulski","year":"2005","unstructured":"Nadulski T, Pragst F, Weinberg G et al (2005) Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. Ther Drug Monit 27:799\u2013810. https:\/\/doi.org\/10.1097\/01.ftd.0000177223.19294.5c","journal-title":"Ther Drug Monit"},{"key":"3232_CR28","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.neubiorev.2019.09.036","volume":"107","author":"AM Freeman","year":"2019","unstructured":"Freeman AM, Petrilli K, Lees R et al (2019) How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. Neurosci Biobehav Rev 107:696\u2013712. https:\/\/doi.org\/10.1016\/j.neubiorev.2019.09.036","journal-title":"Neurosci Biobehav Rev"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03232-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-021-03232-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03232-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T08:05:16Z","timestamp":1641801916000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-021-03232-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["3232"],"URL":"https:\/\/doi.org\/10.1007\/s00228-021-03232-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,18]]},"assertion":[{"value":"28 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial was approved by the Alfred Hospital Ethics Committee (Project No. 591\/19; approved 25 November 2019).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from each participant before any trial-related procedures were performed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written informed consent to have de-identified data submitted for publication was obtained from each participant before any trial-related procedures were performed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Peters is an employee of Canopy Growth Corporation, during which time she has received stock options. She also serves as a consultant to Battelle.\u00a0Dr. MacNair is an employee of Canopy Growth Corporation, during which time she has received stock options.\u00a0Ms. Mosesova was an employee of Canopy Growth Corporation, during which time she received stock options.\u00a0Mr. Land was an employee of Canopy Growth Corporation, during which time he received stock options, and was a prior employee of GW Pharmaceuticals.\u00a0Ms. Turcotte is an employee of Canopy Growth Corporation, during which time she has received stock options.\u00a0Dr. Ware is an employee of Canopy Growth Corporation, during which time he has received stock options.\u00a0Dr. Bonn-Miller is an employee of Canopy Growth Corporation, during which time he has received stock options. He served on the Board of Directors for AusCann Group Holdings Limited, was a prior employee of Zynerba Pharmaceuticals, and has received consulting fees from Tilray Inc.\u00a0None of the other authors reports a conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Conflict of interest"}}]}}